Secondary diagnostic testing for myasthenia gravis when first-line diagnostic tests are negative. Screen for presence of thymoma in patients with myasthenia gravis.
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Plain Red or Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min. 0.5 mL)
Refrigerated. Also acceptable: Frozen
Moderately icteric specimens.
After separation from cells: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month (avoid multiple freeze/thaw cycles)
Effective January 17, 2012
|Positive||0.72 IV or greater|
The presence of titin antibody is associated with late onset of myasthenia gravis (MG) and a variable risk for thymoma. Titin antibody may be detected in 20-40 percent of all patients with MG; higher frequency in older population as a whole.
Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
- Tintin Ab